[go: up one dir, main page]

GB9909392D0 - Treatment, imaging and diagnosis of disease - Google Patents

Treatment, imaging and diagnosis of disease

Info

Publication number
GB9909392D0
GB9909392D0 GBGB9909392.4A GB9909392A GB9909392D0 GB 9909392 D0 GB9909392 D0 GB 9909392D0 GB 9909392 A GB9909392 A GB 9909392A GB 9909392 D0 GB9909392 D0 GB 9909392D0
Authority
GB
United Kingdom
Prior art keywords
diagnosis
imaging
disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9909392.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Horizons Ltd
Original Assignee
Imperial Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Cancer Research Technology Ltd filed Critical Imperial Cancer Research Technology Ltd
Priority to GBGB9909392.4A priority Critical patent/GB9909392D0/en
Publication of GB9909392D0 publication Critical patent/GB9909392D0/en
Priority to AU44184/00A priority patent/AU4418400A/en
Priority to PCT/GB2000/001446 priority patent/WO2000064480A1/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/14Peptides, e.g. proteins
    • A61K49/16Antibodies; Immunoglobulins; Fragments thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB9909392.4A 1999-04-24 1999-04-24 Treatment, imaging and diagnosis of disease Ceased GB9909392D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB9909392.4A GB9909392D0 (en) 1999-04-24 1999-04-24 Treatment, imaging and diagnosis of disease
AU44184/00A AU4418400A (en) 1999-04-24 2000-04-13 Treatment, imaging and diagnosis of disease using an agent which binds alfa5-integrin
PCT/GB2000/001446 WO2000064480A1 (en) 1999-04-24 2000-04-13 Treatment, imaging and diagnosis of disease using an agent which binds alfa5-integrin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9909392.4A GB9909392D0 (en) 1999-04-24 1999-04-24 Treatment, imaging and diagnosis of disease

Publications (1)

Publication Number Publication Date
GB9909392D0 true GB9909392D0 (en) 1999-06-23

Family

ID=10852148

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9909392.4A Ceased GB9909392D0 (en) 1999-04-24 1999-04-24 Treatment, imaging and diagnosis of disease

Country Status (3)

Country Link
AU (1) AU4418400A (en)
GB (1) GB9909392D0 (en)
WO (1) WO2000064480A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539247A4 (en) * 2002-07-16 2007-08-29 Univ New Jersey Med INTEGRATES ALPHA 5 BETA 1 AND ITS ABILITY TO REGULATE THE CELL SURVIVAL PATH
WO2004069281A1 (en) * 2003-01-30 2004-08-19 The General Hospital Corporation Bifunctional molecules comprising at least one integrin-binding and their use in imaging and therapy of angiogenesis and related disorders
EA013323B1 (en) * 2004-12-09 2010-04-30 Сентокор, Инк. Anti-integrin immunoconjugates, methods and uses
CA2646611A1 (en) 2006-03-21 2008-05-22 Genentech, Inc. Combinatorial therapy
US20080038190A1 (en) * 2006-08-11 2008-02-14 Simpson Thomas J Composition apparatus and method for use in imaging
HUE027911T2 (en) 2007-09-26 2016-11-28 Genentech Inc Novel antibodies
CN102365297B (en) 2009-03-25 2014-10-29 霍夫曼-拉罗奇有限公司 Novel anti-α5β1 antibody and its application
US11634470B2 (en) * 2015-10-23 2023-04-25 Jai Prakash Integrin binding peptides and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2861692A (en) * 1991-10-18 1993-05-21 Beth Israel Hospital Association, The Vascular permeability factor targeted compounds
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
ATE423570T1 (en) * 1998-05-08 2009-03-15 Univ California METHOD FOR DETECTING AND INHIBITING ANGIOGENESIS

Also Published As

Publication number Publication date
WO2000064480A1 (en) 2000-11-02
AU4418400A (en) 2000-11-10

Similar Documents

Publication Publication Date Title
GB9903841D0 (en) Diagnosis and treatment of cancer
AU2002303295B2 (en) Diagnosis and treatment of neural disease and injury using microvoltammetry
HUP0401127A3 (en) Treatment and diagnosis of macrophage disease
AU2002367535A8 (en) Diagnosis and treatment of vascular disease
AU2002323258A1 (en) Diagnosis and treatment of vascular disease
AU2001275176A1 (en) Cardiac disease treatment and device
AU2001249835A1 (en) Diagnosis and treatment of alzheimer's disease
GB9909966D0 (en) Analysis of fundus images
IL144981A0 (en) Treatment of autoimmune disease
IL163547A0 (en) Use of the axl receptor for diagnosis and treatment of renal disease
AU2002326813A1 (en) Diagnosis and treatment of vascular disease
AU2003210266A8 (en) Treatment, diagnosis and imaging of disease
GB2353477B (en) Medical endoscope
AU2002222108A1 (en) Diagnosis and treatment of alzheimer's disease
GB9909392D0 (en) Treatment, imaging and diagnosis of disease
GB9811598D0 (en) Diagnosis and treatment of cancer
AU5550800A (en) Diagnosis and treatment of alzheimer's disease
AU2002341880A1 (en) Diagnosis and treatment of vascular disease
AU4654500A (en) Prevention, diagnosis and treatment of lyme disease
IL142581A (en) Medicament for treating heart disease
AU2002341604A1 (en) Diagnosis and treatment of vascular disease
GB0001443D0 (en) Medical endoscope
AU2001253024A1 (en) Diagnosis and treatment of gastrointestinal disease
GB9908059D0 (en) Diagnosis and treatment of diseases
AU2001296477A1 (en) Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)